Clinical Trial

GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 30, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma. The main purposes of this study include: ① To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the GPC-3 targeted fluorophore. ② To validate the safety and effectiveness of the designed GPC-3 targeted fluorophore for clinical application.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-09-11.
Trial Details
NCT Number NCT05047510
Lead Sponsor Chinese Academy of Sciences
Conditions Hepatocellular Carcinoma
Enrollment 60 participants
Start Date 2021-09-10
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-08-30